<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03507478</url>
  </required_header>
  <id_info>
    <org_study_id>20102</org_study_id>
    <nct_id>NCT03507478</nct_id>
  </id_info>
  <brief_title>An Evaluation of a Customized Insole to Provide Relief From Heel Pain Due to Plantar Fasciitis or General Heel Pain When Used in Footwear Over a Period of Four Weeks</brief_title>
  <official_title>An Evaluation of a Customized Insole to Provide Relief From Heel Pain Due to Plantar Fasciitis or General Heel Pain When Used in Footwear Over a Period of Four Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial will be to demonstrate the ability of a 3/4 length foam&#xD;
      insole to provide relief from pain due to plantar fasciitis or general heel pain when used in&#xD;
      footwear over a 4-week period of time&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Actual">July 26, 2018</completion_date>
  <primary_completion_date type="Actual">July 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Foot pain assessment of plantar fasciitis heel pain using the 100 mm VAS</measure>
    <time_frame>Up to 5 weeks (including screening)</time_frame>
    <description>VAS (Visual Analog Scale):&#xD;
100 mm with 0 = no pain and 100 = Worst pain possible</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Foot pain assessment of general heel pain using the 100 mm VAS</measure>
    <time_frame>Up to 5 weeks (including screening)</time_frame>
    <description>VAS (Visual Analog Scale):&#xD;
100 mm with 0 = no pain and 100 = Worst pain possible</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Foot Comfort/Discomfort is assessed utilizing a 7-point Comfort/Discomfort Likert scale</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoe/foot Fit with use in shoes is assessed utilizing a 7-point Likert scale</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with AEs</measure>
    <time_frame>Up to 5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with SAEs</measure>
    <time_frame>Up to 5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Foot Orthoses</condition>
  <arm_group>
    <arm_group_label>BPI1000013</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects suffering from pain associated with plantar fasciitis or general heel pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BPI1000013</intervention_name>
    <description>Foam insole</description>
    <arm_group_label>BPI1000013</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be generally healthy and 18 to 65 years of age inclusive;&#xD;
&#xD;
          -  Male subjects must have measured foot sizes between size 8.5 and 15. Female subjects&#xD;
             must have measured foot sizes between size 8 and 10.5;&#xD;
&#xD;
          -  Subjects must be willing to designate 2 pair of shoes with a maximum heel height of 1&#xD;
             ¼ inches, of either casual, work or type of sneakers, for approval of use during the&#xD;
             trial. A maximum of 25% of subjects can be sneaker wearers. The 2nd pair of presented&#xD;
             shoes must be of the same type. Subjects that wear shoes in the work category may&#xD;
             qualify a single pair of shoes as long as the subject wears the same pair of shoes to&#xD;
             work every day;&#xD;
&#xD;
          -  Subjects must indicate that they currently have heel pain and that they experience&#xD;
             heel pain at the end of the day. Subjects that have plantar fasciitis will be&#xD;
             identified by the presence of acute pain in the morning upon taking their first steps;&#xD;
&#xD;
          -  Subjects must report Heel pain of ≥20 mm to ≤90 mm at the end of their day [assessed&#xD;
             on a 100 mm Visual Analog Scale (VAS), where 0=no pain and 100=worst pain possible] at&#xD;
             baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with heel pain due to recent heel spurs, stress fracture or other structural&#xD;
             issues;&#xD;
&#xD;
          -  Subjects with self-reported alcohol consumption that exceeds moderate consumption (&gt;2&#xD;
             alcoholic beverages per day);&#xD;
&#xD;
          -  Subjects with a self-reported history or suspicion of psychiatric disorder, alcohol or&#xD;
             drug abuse, including, but not limited to: barbiturate, amphetamine, benzodiazepine,&#xD;
             cocaine, opiate, methamphetamine, cannabis abuse;&#xD;
&#xD;
          -  Subjects that have received or used an Investigational New Drug in the past 30 days;&#xD;
&#xD;
             = Subjects that have been enrolled in the last two weeks or are currently&#xD;
             participating in a product performance research study or any other type of research,&#xD;
             marketing, or product performance study;&#xD;
&#xD;
          -  Subjects who are nursing, pregnant, or planning to become pregnant during the course&#xD;
             of the study (self-reported);&#xD;
&#xD;
          -  Subjects who are employed or have family members employed by Market Research/Marketing&#xD;
             Consulting, Manufacturing, Distribution, Retail or Marketing of any type of personal&#xD;
             care product, drug product, or pharmaceutical;&#xD;
&#xD;
          -  Subjects who have diabetes, circulatory problems, open wounds, and lack of sensation&#xD;
             in their feet or any problems that would make insole wear uncomfortable or&#xD;
             inappropriate;&#xD;
&#xD;
          -  Subjects who wear physician-prescribed orthotic insoles or prescription shoes;&#xD;
&#xD;
          -  Subjects who have had a traumatic injury to the lower extremity (deemed of non-overuse&#xD;
             nature), which in the opinion of the examining Investigator would interfere with the&#xD;
             study evaluations;&#xD;
&#xD;
          -  Subjects whose condition requires surgery or other medical intervention or who have&#xD;
             undergone foot back or knee surgery within the past 3 months or with any planned&#xD;
             surgeries and/or invasive medical procedures during the course of the study;&#xD;
&#xD;
          -  Subjects who are currently taking an opioid-based pain medication or have taken such&#xD;
             medication within 2 months prior to Visit 1;&#xD;
&#xD;
          -  Subjects who are taking any chronic pain medication (prescription or OTC) for at least&#xD;
             2 months, who do not agree to continue taking it at the same dose and regimen&#xD;
             throughout the study;&#xD;
&#xD;
          -  Subjects who have severely painful bunions, warts, corns and/or calluses, or severely&#xD;
             overlapping toes, or lesions on the bottom of their foot;&#xD;
&#xD;
          -  Subjects who have sensitivities or allergies to plastics or adhesives;&#xD;
&#xD;
          -  Subjects who have conditions which in the opinion of the investigator preclude&#xD;
             participation for scientific reasons of compliance, or for reasons of subject's&#xD;
             safety;&#xD;
&#xD;
          -  Subjects who have any condition that would make study participation inappropriate, as&#xD;
             determined by the examining Investigator or designee;&#xD;
&#xD;
          -  Subjects with a self-reported history of immunosuppression/immune deficiency disorders&#xD;
             or currently using immunosuppressive medications (e.g., azathioprine, belimumab,&#xD;
             cyclophosphamide, Enbrel, Imuran, Humira, mycophenolate mofetil, methotrexate,&#xD;
             prednisone, Remicade, Stelara.), and/or radiation as determined by study&#xD;
             documentation;&#xD;
&#xD;
          -  Previous assignment to treatment during this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thomas J. Stephens &amp; Associates, Inc.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephens &amp; Associates, Inc.</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>April 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2018</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

